Non-small cell lung cancer is the most common type of lung cancer, accounting for about 80 to 85 percent of all lung cancer diagnoses

Non-small cell lung cancer (NSCLC) is a category of lung cancer defined by the size and appearance of cancer cells under a microscope. The cells are larger than those found in small cell lung cancer, which is why they earned the name "non-small cell." This distinction matters because it changes how the cancer behaves, how fast it spreads, and which treatments are most likely to work.

NSCLC grows more slowly than small cell lung cancer and is less likely to spread to distant parts of the body early on. However, it is still serious and requires prompt medical attention. The cancer can originate in any part of the lung—the upper lobes, lower lobes, or the small air sacs where oxygen enters the bloodstream.

Most people diagnosed with NSCLC have a history of smoking or were exposed to secondhand smoke, but the disease also occurs in people who have never smoked. Other risk factors include radon exposure, asbestos, air pollution, and a family history of lung cancer.

Key Takeaways

  • Non-small cell lung cancer is defined by cell size under a microscope and accounts for the majority of lung cancer cases.
  • The three main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each arising from different cell types in the lung.
  • NSCLC grows more slowly than small cell lung cancer but still requires treatment to prevent spread to other organs.
  • Diagnosis involves imaging tests like CT scans and a biopsy to confirm the cancer type and stage.
  • Treatment options include surgery, radiation, chemotherapy, and targeted therapies, chosen based on the cancer stage and patient health.

The three main subtypes of non-small cell lung cancer

Adenocarcinoma is the most common subtype, making up about 40 percent of NSCLC cases. It arises from mucus-secreting cells in the outer regions of the lung and tends to grow more slowly than other subtypes. Adenocarcinoma is the most common type found in people who have never smoked.

Squamous cell carcinoma accounts for about 25 to 30 percent of NSCLC cases. It develops in flat cells that line the airways in the center of the lung. This subtype is more strongly associated with a smoking history than adenocarcinoma.

Large cell carcinoma is the least common subtype, representing about 10 to 15 percent of NSCLC cases. It can appear in any part of the lung and tends to grow and spread more quickly than adenocarcinoma or squamous cell carcinoma. Because of this faster growth pattern, it is often diagnosed at a later stage.

How NSCLC is diagnosed and staged

Diagnosis begins with imaging. A CT scan (computed tomography) of the chest shows the size and location of any tumors. If a suspicious area is found, a biopsy is performed to confirm the diagnosis. A biopsy involves removing a small sample of tissue—either through a needle inserted through the skin, a tube passed down the throat, or during a surgical procedure—and examining it under a microscope to identify the cancer cells and subtype.

Once NSCLC is confirmed, the cancer is staged to determine how far it has spread. Staging uses a system called TNM: T describes the size and location of the tumor, N describes whether lymph nodes are involved, and M describes whether the cancer has spread to distant organs. Stages range from 1 (smallest, most localized) to 4 (spread to distant sites). Staging guides treatment decisions and helps estimate prognosis.

Additional tests may include PET scans to check for spread to bones or the brain, blood tests, and pulmonary function tests to measure how well the lungs work. These tests help doctors understand the full extent of the cancer and whether the patient's lungs can tolerate certain treatments.

How NSCLC differs from small cell lung cancer

Small cell lung cancer (SCLC) makes up about 15 to 20 percent of lung cancer cases and behaves very differently from NSCLC. SCLC cells are smaller and more densely packed, and the cancer grows and spreads much faster. By the time SCLC is diagnosed, it has often already spread beyond the lung to the brain, bones, or liver.

Because SCLC spreads so quickly, it is typically treated with chemotherapy and radiation rather than surgery. NSCLC, by contrast, is more likely to be caught at an earlier stage when surgery to remove the tumor is an option. The five-year survival rate for NSCLC is higher than for SCLC, in part because of these differences in growth rate and the ability to treat it surgically.

Both types are strongly associated with smoking, but NSCLC is more common overall and is the type most often found in people without a smoking history.

Treatment options for non-small cell lung cancer

Surgery is often the first treatment for early-stage NSCLC if the patient's lung function is adequate. A surgeon may remove part of the lung (lobectomy) or the entire lung (pneumonectomy), along with nearby lymph nodes. Surgery offers the best chance of cure for stages 1 through 3A, provided the cancer has not spread too far.

Radiation therapy uses high-energy beams to kill cancer cells. It may be used alone for patients who cannot have surgery, or combined with chemotherapy. Stereotactic body radiation therapy (SBRT) delivers high doses to a small area in fewer sessions and is sometimes used for early-stage tumors.

Chemotherapy uses drugs to kill cancer cells throughout the body. It is often given before surgery to shrink the tumor, after surgery to destroy remaining cells, or as the main treatment for advanced NSCLC. Chemotherapy can cause side effects including nausea, hair loss, and fatigue, but these effects are usually temporary.

Targeted therapies are drugs designed to attack specific mutations in cancer cells. For example, some NSCLC tumors have mutations in the EGFR gene or ALK gene. Drugs that target these mutations can be very effective and often have fewer side effects than traditional chemotherapy. Your doctor will test the tumor for these mutations to determine if a targeted therapy is an option.

Immunotherapy helps the immune system recognize and attack cancer cells. Checkpoint inhibitors are a type of immunotherapy that has shown benefit in NSCLC, particularly for advanced stages. These drugs may be used alone or combined with chemotherapy.

Prognosis and survival rates for NSCLC

Prognosis depends on the stage at diagnosis, the subtype, whether the tumor has specific mutations, and the patient's overall health. Early-stage NSCLC has a better prognosis than advanced disease. The five-year survival rate for stage 1 NSCLC is around 60 percent, while stage 4 is around 5 to 10 percent. However, these are population averages, and individual outcomes vary widely.

Advances in treatment over the past decade have improved survival rates, particularly for advanced NSCLC. Targeted therapies and immunotherapy have extended survival for patients with specific tumor mutations or high levels of a protein called PD-L1. Clinical trials continue to test new combinations of treatments and new drugs.

Survival also depends on factors outside the cancer itself, such as age, smoking status, and whether the patient has other health conditions. A doctor can discuss what the statistics mean for an individual patient based on their specific situation.

Living with and after NSCLC treatment

During treatment, side effects vary depending on the type of therapy. Surgery may cause pain and temporary shortness of breath as the lungs heal. Chemotherapy and radiation can cause fatigue, nausea, and skin irritation. Targeted therapies and immunotherapy often have different side effect profiles and may be better tolerated by some patients.

After treatment ends, follow-up care is important. Patients typically have CT scans at regular intervals to check for recurrence. The frequency of scans decreases over time if no cancer is found. Some patients experience long-term side effects from treatment, such as shortness of breath or difficulty swallowing, and rehabilitation or supportive care can help manage these.

Lifestyle changes such as quitting smoking (if applicable), managing stress, eating well, and staying active can support recovery and overall health. Support groups and counseling are also available for patients and families dealing with a lung cancer diagnosis.

Frequently Asked Questions

Can you get non-small cell lung cancer if you have never smoked?

Yes. While smoking is the leading risk factor, about 10 to 15 percent of NSCLC cases occur in people who have never smoked. Other risk factors include radon exposure, secondhand smoke, asbestos, air pollution, and family history. Adenocarcinoma is the subtype most commonly found in never-smokers.

What is the difference between stage 3 and stage 4 NSCLC?

Stage 3 NSCLC means the cancer is in the lung and nearby lymph nodes but has not spread to distant organs. Stage 4 means the cancer has spread to other parts of the body, such as the brain, bones, or liver. Stage 3 may be treated with surgery, chemotherapy, and radiation, while stage 4 is typically treated with chemotherapy, targeted therapy, or immunotherapy.

Is NSCLC hereditary?

NSCLC itself is not inherited, but a family history of lung cancer increases your risk of developing it. Some people inherit genetic mutations that make them more susceptible to cancer, but most NSCLC cases result from environmental exposures and random mutations that occur during a person's lifetime.

How long does treatment for NSCLC usually take?

Surgery typically takes a few hours, with recovery taking several weeks. Chemotherapy is usually given in cycles over several months. Radiation therapy is often delivered daily for two to six weeks. Targeted therapy and immunotherapy may be continued for months or years if they are working. Your doctor will outline a specific treatment timeline based on your cancer stage and type.

Can NSCLC come back after treatment?

Yes, recurrence is possible even after successful treatment. This is why follow-up imaging and doctor visits are important. Recurrence can happen in the lung where the original cancer was, in other parts of the lung, or in distant organs. If recurrence occurs, additional treatment options may be available depending on the location and extent of the new cancer.